Summary
The absolute bioavailability of fenspiride has been studied in twelve healthy volunteers. It was administered IV and orally in single doses of 80 mg fenspiride hydrochloride according to a randomised crossover pattern.
Following IV administration, the plasma clearance of fenspiride was about 184 ml·min−1, and its apparent volume of distribution was moderately large (2151).
When given orally as a tablet, fenspiride exhibited fairly slow ab- sorption; the maximum plasma concentration (206 ng·ml−1) was achieved 6 h after administration. The absolute bioavailability was almost complete (90%). The tablet had slow release characteristics. The elimination half-life obtained from the plasma data was 14 to 16 h independent of the route of administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carre P, Pipy B, Pinelli E, Forgue MF, Beraud M, Didier A, Leophonte P (1991) In vitro effects of fenspiride on the production of free oxygen radicals, prostaglandins and leukotrienes by guinea-pig alveolar macrophages. Eur Respir Rev 1: 79–85
Chapelain B, Neliat G, Bodinier MC, Jean T, Evrard Y, Gargouil YM (1991) Role of the epithelium in the action of fenspiride on the isolated guinea-pig and rat trachea. Eur Respir Rev 1: 86–92
Evrard Y, Kato G, Bodinier MC, Chapelain B (1991) Fenspiride and inflammation in experimental pharmacology. Eur Respir Rev 1: 93–100
Giacchero G, Taranger J (1982) Pneumorel retard au long cours dans le traitement des bronchites chroniques. Vie Méd 63: 791–794
Kafe H (1984) Intérêt du Pneumorel 80 mg dans le traitement de l'insuffisance respiratoire chronique. Vie Méd 65: 200–203
Turrisi E, Mea A, Bruno G, Vitagliano A (1984) Studio controllato del fenspiride ritardo in ambito pneumologico. Clin Ther 111: 339–346
Olivieri D, Del Donno M (1987) Etude de l'action du fenspiride sur la clairance mucociliaire chez le bronchitique chronique. JIM 96: 395–398
Leophonte P, Thack KS, Voigt JJ, Rouquet RM, Didier A (1986) Le fenspiride (Pneumorel 80 mg) dans le traitement des bronchopneumopathies chroniques obstructives. Vie Méd 23–24: 1047–1051
Akoun G, Arnaud F, Blanchon F, Botto JM, Cerf C, Clavier J, Derenne JP, Leophonte P, Nouvet G, Paramelle B, Patron P, Prefaut C, Verlardocchio JM (1991) Effects of fenspiride on airway function and blood gases in stable COPD patients. Eur Respir Rev 1: 111–125
Evrard Y, Lhoste F, Advenier C, Duhault J (1986) Le fenspiride et le système broncho-pulmonaire: nouvelle approche pharmacologique. Semaine Hôp 62: 1375–1381
Megel H, Holmes P, Zalipsky J, Schemano I, Beiler JM (1973) Fenspiride 14C: its distribution, excretion and metabolism in the rat. Arch Int Pharmacodyn Ther 201: 90–99
Jeanniot JP, Chezaubernard C (1991) Pharmacokinetic properties of fenspiride: an update. Eur Resp Rev 1: 101–104
Sauveur C, Baune A, Vergnes N, Jeanniot JP (1989) Quantitative determination of fenspiride in human plasma and urine by liquid chromatography with electrochemical or ultraviolet detection J Pharm Biomed Anal 7: 1799–1804
Weiner DL (1986) NONLIN 84/PC NONLIN: software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol 8: 625–628
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Montes, B., Catalan, M., Roces, A. et al. Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial. Eur J Clin Pharmacol 45, 169–172 (1993). https://doi.org/10.1007/BF00315501
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315501